Clinical trials: Healthy Tissue
- Condition Healthy Tissue
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
HPV Infections, Cervical Cancer
Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
The study will evaluate the immunogenicity and safety of 9-valent HPV recombinant vaccine in Chinese healthy females16 to 26 years of age.
- Conditions
- HPV Infections, Cervical Cancer, Vulvar Cancer, Vaginal Cancer
- Trial name
- NCT05372016
- Testing
- Experimental: Experimental: 9-valent Human Papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52, 58), Active Comparator: GARDASIL ®9
- Where
- China
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
HPV Infection, HPV-Related Carcinoma
To Evaluate the Safety and Immunogenicity of 15-valent HPV Recombinant Vaccine in Chinese People Aged 9-45 Years
To evaluate the safety and Immunogenicity of 15-valent HPV vaccine in 9-45year-old participants.
- Conditions
- HPV Infection, HPV-Related Carcinoma, HPV-Related Intraepithelial Neoplasia, Genital Wart
- Trial name
- NCT06756269
- Testing
- Medium dose for 15-HPV vaccine, High dose for 15-HPV vaccine, 9-HPV vaccine
- Where
- China
- Volunteers
- 330 people, healthy volunteers welcome
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
Diaper Rash
Infant Microbiome in Diaper Rash
The objective of this study is to evaluate the microbiome composition of infant's (9-12 month) skin experiencing diaper rash in order to determine if the onset and severity of erythema associated with diaper rash is influenced by…
- Trial name
- NCT02893501
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Kimberly-Clark Corporation
Papillomavirus Infections
GARDASIL™ Study in Healthy Females Between 9 and 26 Years of Age in Sub-Saharan Africa (V501-046)
The study is designed to determine the safety, tolerability and immunogenicity of a 3-dose regimen of GARDASIL™ administered to healthy females between 9 and 26 years of age, in Sub-Saharan Africa.
- Trial name
- NCT01245764
- Testing
- Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (GARDASIL™)
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Cancer, Healthy
Collection and Distribution of Biospecimens for Novel Research Uses
iSpecimen aims to create a clinical partner network of hospitals, laboratories, academic institutions, and other healthcare organizations ("institutions") capable of providing researchers and educators ("researchers") with…
- Conditions
- Cancer, Healthy, Gastrointestinal Complication, Autoimmune Diseases
- Trial name
- NCT03848962
- Where
- 2 sites in United States
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- iSpecimen Inc
Dermatitis, Atopic
Curing Atopic Dermatits in Children With a Commerical Medical Device and Maintaining Healthy Skin by Using a New Cosmetic Product
1. Curing mild atopic dermatis in children with a commerical medical device (Bepanthen Itch Relief Cream). 2. Maintaining healthy skin by using a new cosmetic Bepanthen product or a commercially available cosmetic product
- Trial name
- NCT02615561
- Testing
- Bepanthen Itch Relief Cream: Phoenix 2 (Bepanthen Sensiderm, BAY207543), New cosmetic Bepanthen product: Pumpkin (BAY207543), Stelatopia (cosmetic comparator)
- Where
- 14 sites in Germany
- Volunteers
- 136 people
- Sponsor
- Bayer
Cervical Cancer, Genital Wart
Phase III Study Comparing the Immunogenicity of 9-valent HPV Recombinant Vaccine and Gardasil-9
This study will evaluate the immunogenicity and safety of Zerun 9-valent HPV recombinant vaccine in healthy female 16-26 years of age by comparing with GARDASIL®9.
- Conditions
- Cervical Cancer, Genital Wart, CIN, VIN
- Trial name
- NCT05580341
- Testing
- Zerun HPV-9, GARDASIL ®9
- Where
- China
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Shanghai Zerun Biotechnology Co.,Ltd
Human Papillomavirus Infection
A Study to Evaluate the Immunogenicity and Safety of HPV Vaccine in Healthy Female Participants Aged 9-26 Years in China
The study is to evaluate immune response induced by 9-valent HPV study vaccine is non-inferior to those induced by GARDASIL® 9 administrated with 3-dose schedule in female participants aged 20-26 years in China, if the immune…
- Trial name
- NCT05662020
- Testing
- Recombinant Nonavalent (types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia coli), GARDASIL® 9
- Where
- China
- Volunteers
- 2,750 people, healthy volunteers welcome
- Sponsor
- Beijing Health Guard Biotechnology, Inc
HPV Infections, Cervical Cancer Stage IIa
Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years
This phase 3 study will evaluate the immunogenicity and safety of Quadrivalent HPV recombinant vaccine in Chinese females aged 9 to 26 years
- Conditions
- HPV Infections, Cervical Cancer Stage IIa, Vaginal Cancer, Genital Wart
- Trial name
- NCT05027776
- Testing
- 2-doses Group among 9-14 years, 3-doses Group among 9-19 years, 3-doses Group among 20-26 years
- Where
- China
- Volunteers
- 1,348 people, healthy volunteers welcome
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
Normal Human Subjects
Single Photon Emission Computed Tomography of the Normal Human Brain
The objective of the study is to acquire a database of Single Photon Emission Computed Tomographic (SPECT) studies of the brains of normal human subjects in resting and concentrating states.
- Trial name
- NCT01203891
- Where
- United States
- Volunteers
- 97 people, healthy volunteers welcome
- Sponsor
- Amen Clinics, Inc.
Herpes Simplex
Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old
Main goal of this study is to compare the occurrence of serious adverse events (SAEs) between the herpes simplex (gD2-AS04) vaccine group and the Saline control group throughout the study period (up to month 12).
- Trial name
- NCT00224484
- Testing
- GSK208141, Havrix (investigational formulation)
- Where
- 151 sites in United States, Australia and 16 more
- Volunteers
- 5,960 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Dermatitis, Allergic Contact, Infectious Diseases
Incidence of Allergic Manifestations and Infectious Episodes in Healthy Term Infants at Risk for Dysbiosis
This study will evaluate the incidence of allergic manifestations (the first of which is atopic dermatitis) and infectious diseases in children fed with an infant formula under real conditions of use.
- Trial name
- SOPRANO (NCT04182425)
- Testing
- Infant formula
- Where
- France
- Volunteers
- 334 people, healthy volunteers welcome
- Sponsor
- Bledina
Primary Hyperoxaluria
Study of DCR-PHXC-101 in Normal Healthy Volunteers and Patients With Primary Hyperoxaluria
This is a double-blind, placebo-controlled, dose escalation trial of DCR-PHXC in Healthy Volunteers (HVs) and patients with Primary Hyperoxaluria (PH).
- Trial name
- NCT03392896
- Testing
- DCR-PHXC
- Where
- 7 sites in United States, France and 3 more
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Cervical Cancer, Vulvar Cancer
Broad Spectrum HPV (Human Papillomavirus) Vaccine in 16 to 26 Year Old Women (V505-001)
The purpose of this study is to evaluate the safety and immunogenicity of V505 in comparison to GARDASIL (TM)
- Conditions
- Cervical Cancer, Vulvar Cancer, Vaginal Cancer, Genital Warts
- Trial name
- NCT00520598
- Testing
- Comparator: V505 formulation 1, Comparator: V505 formulation 2, Comparator: V505 formulation 3
- Volunteers
- 511 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Diarrhea, Atopic Dermatitis
Cesarean Section Study
Effect, tolerance and safety of a supplementation with a probiotic on the risk of gastrointestinal infections, on growth, and on gut microbiota in healthy newborn term infants born by Cesarean section.
- Trial name
- NCT01992497
- Testing
- Probiotic
- Where
- Germany
- Volunteers
- 721 people, healthy volunteers welcome
- Sponsor
- Société des Produits Nestlé (SPN)
Cervical Cancers, Vulvar Cancer
Evaluate the Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
To evaluate the safety and immunogenicity of the 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female Subjects Aged 9-45 Years.
- Conditions
- Cervical Cancers, Vulvar Cancer, Vaginal Cancer, CIN1
- Trial name
- NCT03676101
- Testing
- 9-valent HPV Recombinant Vaccine
- Where
- China
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
Allergic Conjunctivitis
Study Evaluating the Safety of KetoNaph Ophthalmic Solution in Healthy Volunteers
This study is being conducted to evaluate the safety of KetoNaph ophthalmic solution in healthy adult subjects and in pediatric subjects with a history or family history of ocular allergy.
- Trial name
- NCT01159015
- Testing
- KetoNaph, Vehicle
- Volunteers
- 534 people, healthy volunteers welcome
- Sponsor
- Bausch & Lomb Incorporated
Allergic Conjunctivitis
Safety Study of a Contact Lens With Ketotifen in Healthy, Normal Volunteers
The purpose of this study is to evaluate the safety of a novel contact lens in healthy normal volunteers.
- Trial name
- NCT00889252
- Testing
- contact lens with ketotifen, contact lens
- Where
- United States
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Vistakon Pharmaceuticals
Atopic Dermatitis
Phase 1 Study of QX-4533 in Healthy Volunteers and Patients With Moderate-to-Severe Atopic Dermatitis
The goal of this clinical trial is to evaluate the safety and tolerability of QX-453, an investigational treatment, in healthy Chinese volunteers and patients with moderate-to-severe atopic dermatitis.
- Trial name
- NCT07800104
- Testing
- QX4533
- Where
- China
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- QuantX Biosciences, Inc.
Penile Cancer, Anal Cancer
Evaluate the Safety and Immunogenicity of a 9-valent HPV Vaccine in Chinese Healthy Male Aged 9-45 Year-old
To evaluate the safety and tolerability of the 9vHPV vaccine in Chinese healthy male aged 9 to 45 years.
- Conditions
- Penile Cancer, Anal Cancer, PIN-1, PIN-2
- Trial name
- NCT05518201
- Where
- China
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.